In today's edition of Market Checkup, health-care analysts David Williamson and Max Macaluso take a close look at Johnson & Johnson, the largest health-care company in the Dow. They discuss the key takeaways from Johnson & Johnson's second-quarter results and look at its main opportunities in the medical device, pharmaceutical, and consumer health-care spaces.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Market Checkup: Johnson & Johnson's Second Quarter
The Motley Fool's health-care show Market Checkup for August 13, 2013.
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson and Vertex Pharmaceuticals and owns shares of Dendreon and Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.